Suppr超能文献

NKCC1的抑制机制涉及羧基末端和长程构象偶联。

Inhibition mechanism of NKCC1 involves the carboxyl terminus and long-range conformational coupling.

作者信息

Moseng Mitchell A, Su Chih-Chia, Rios Kerri, Cui Meng, Lyu Meinan, Glaza Przemyslaw, Klenotic Philip A, Delpire Eric, Yu Edward W

机构信息

Department of Pharmacology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.

Department of Anesthesiology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

出版信息

Sci Adv. 2022 Oct 28;8(43):eabq0952. doi: 10.1126/sciadv.abq0952.

Abstract

The Na-K-2Cl cotransporter-1 (NKCC1) is an electroneutral Na-dependent transporter responsible for simultaneously translocating Na, K, and Cl ions into cells. In human tissue, NKCC1 plays a critical role in regulating cytoplasmic volume, fluid intake, chloride homeostasis, and cell polarity. Here, we report four structures of human NKCC1 (hNKCC1), both in the absence and presence of loop diuretic (bumetanide or furosemide), using single-particle cryo-electron microscopy. These structures allow us to directly observe various novel conformations of the hNKCC1 dimer. They also reveal two drug-binding sites located at the transmembrane and cytosolic carboxyl-terminal domains, respectively. Together, our findings enable us to delineate an inhibition mechanism that involves a coupled movement between the cytosolic and transmembrane domains of hNKCC1.

摘要

钠-钾-2氯协同转运蛋白1(NKCC1)是一种电中性的钠依赖性转运蛋白,负责将钠、钾和氯离子同时转运到细胞内。在人体组织中,NKCC1在调节细胞质体积、液体摄入、氯稳态和细胞极性方面发挥着关键作用。在此,我们使用单颗粒冷冻电子显微镜报告了人NKCC1(hNKCC1)在不存在和存在袢利尿剂(布美他尼或呋塞米)情况下的四种结构。这些结构使我们能够直接观察到hNKCC1二聚体的各种新构象。它们还揭示了分别位于跨膜和胞质羧基末端结构域的两个药物结合位点。总之,我们的研究结果使我们能够描绘出一种抑制机制,该机制涉及hNKCC1胞质和跨膜结构域之间的耦合运动。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63b1/9616490/3f00603c1f86/sciadv.abq0952-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验